- Home
- TAOP vs VIVS Comparison
TAOP vs VIVS Comparison
Compare TAOP & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAOP
- VIVS
- Stock Information
- Founded
- TAOP 1993
- VIVS 2007
- Country
- TAOP China
- VIVS United States
- Employees
- TAOP N/A
- VIVS N/A
- Industry
- TAOP Computer Software: Prepackaged Software
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TAOP Technology
- VIVS Health Care
- Exchange
- TAOP Nasdaq
- VIVS Nasdaq
- Market Cap
- TAOP 4.8M
- VIVS 5.0M
- IPO Year
- TAOP N/A
- VIVS N/A
- Fundamental
- Price
- TAOP $4.13
- VIVS $2.21
- Analyst Decision
- TAOP
- VIVS
- Analyst Count
- TAOP 0
- VIVS 0
- Target Price
- TAOP N/A
- VIVS N/A
- AVG Volume (30 Days)
- TAOP 27.7K
- VIVS 70.9K
- Earning Date
- TAOP 09-04-2025
- VIVS 08-05-2025
- Dividend Yield
- TAOP N/A
- VIVS N/A
- EPS Growth
- TAOP N/A
- VIVS N/A
- EPS
- TAOP N/A
- VIVS N/A
- Revenue
- TAOP $36,672,512.00
- VIVS $144,000.00
- Revenue This Year
- TAOP N/A
- VIVS $42.38
- Revenue Next Year
- TAOP N/A
- VIVS $15.42
- P/E Ratio
- TAOP N/A
- VIVS N/A
- Revenue Growth
- TAOP N/A
- VIVS 32.11
- 52 Week Low
- TAOP $3.56
- VIVS $1.41
- 52 Week High
- TAOP $29.40
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- TAOP 37.83
- VIVS N/A
- Support Level
- TAOP $4.09
- VIVS N/A
- Resistance Level
- TAOP $4.51
- VIVS N/A
- Average True Range (ATR)
- TAOP 0.41
- VIVS 0.00
- MACD
- TAOP 0.03
- VIVS 0.00
- Stochastic Oscillator
- TAOP 33.02
- VIVS 0.00
About TAOP Taoping Inc.
Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.